中枢神経系バイオマーカーの世界市場

中枢神経系バイオマーカーの世界市場は2030年までに88億米ドルに達する見込み

2024年に59億米ドルと推定される中枢神経系バイオマーカーの世界市場は、2024年から2030年にかけてCAGR 7.0％で成長し、2030年には88億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである安全性バイオマーカーは、CAGR 8.0%を記録し、分析期間終了までに46億米ドルに達すると予測されます。有効性バイオマーカー分野の成長率は、分析期間のCAGRで6.7％と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 11.1％で成長予測

米国の中枢神経系バイオマーカー市場は、2024年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.8%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の中枢神経系バイオマーカー市場- 主要動向と促進要因まとめ

なぜ中枢神経系バイオマーカーの需要が増加しているのか？

アルツハイマー病、パーキンソン病、多発性硬化症、外傷性脳損傷などの神経疾患の有病率の上昇は、中枢神経系（CNS）バイオマーカーの需要を促進する重要な要因です。これらのバイオマーカーは、早期診断、疾患進行モニタリング、治療効果評価に不可欠な役割を果たしています。世界人口の高齢化と神経変性疾患に対する意識の高まりにより、精密な診断ツールに対するニーズはかつてないほど高まっています。さらに、製薬企業やバイオテクノロジー企業は、個別化医療のための新規バイオマーカーを同定するための研究開発を強化しています。標的治療に対する需要の高まりは、特に神経変性疾患や精神疾患の分野におけるバイオマーカー探索への投資拡大を促しています。精密医療が普及するにつれ、中枢神経系のバイオマーカーは治療方針の決定や患者の転帰の改善に不可欠なものとなると思われます。

技術の進歩は中枢神経系バイオマーカー調査をどのように強化しているのか？

ゲノミクス、プロテオミクス、メタボロミクスを含むオミクス技術の革新は、中枢神経系バイオマーカー研究に革命をもたらしています。ハイスループットシーケンスと高度な分子プロファイリング技術により、より高い特異性と感度で新規バイオマーカーの同定が可能になっています。人工知能（AI）と機械学習も膨大なデータセットの解析に採用され、バイオマーカーに基づく診断の精度が向上しています。さらに、リキッドバイオプシー技術や非侵襲的な脳脊髄液（CSF）バイオマーカーアッセイの人気が高まっており、神経疾患を検出するための侵襲性の低い方法が提供されています。ウェアラブルバイオセンサーや遠隔モニタリングツールを含むデジタルヘルス技術の統合は、バイオマーカーの応用範囲を拡大しています。これらの進歩により、中枢神経系バイオマーカーの商業化が加速し、神経疾患管理の全体的な効率が向上すると期待されます。

CNSバイオマーカーの成長を促進する市場動向とは？

バイオマーカー主導の医薬品開発の採用拡大が、中枢神経系バイオマーカー市場を形成する主な動向の1つです。製薬会社は、薬剤の有効性と患者の層別化を改善するために、臨床試験にバイオマーカーを組み込むことが増えています。FDAやEMAなどの規制当局もバイオマーカー検証プログラムを支援しており、より迅速な医薬品承認と個別化治療戦略を促進しています。もう一つの大きな動向は、分子、画像、デジタルバイオマーカーを組み合わせたマルチモーダルバイオマーカーアプローチの台頭です。PETやMRIベースのバイオマーカーなどの神経画像技術の進歩は、特にアルツハイマー病や多発性硬化症などの疾患において、疾患の進行をより正確に可視化することを可能にしています。さらに、学界、バイオテクノロジー企業、ヘルスケア機関の連携がイノベーションを促進し、バイオマーカーの発見と検証を加速しています。

中枢神経系バイオマーカー市場の主な成長促進要因は？

中枢神経系バイオマーカー市場の成長は、神経疾患の負担増、精密医療の採用拡大、バイオマーカー探索の技術進歩など、いくつかの要因によってもたらされます。早期診断ソリューションに対する需要の高まりや、バイオマーカーに基づく医薬品開発パイプラインの拡大が、市場の成長をさらに後押ししています。さらに、バイオマーカーの標準化と検証に対する規制の後押しが、製薬会社による臨床試験へのバイオマーカーの統合を促しています。特に神経変性疾患や精神疾患におけるバイオマーカーに基づくコンパニオン診断の拡大は、市場関係者に新たなビジネスチャンスをもたらしています。ヘルスケア業界が疾患の早期発見と個別化治療戦略を優先し続ける中、中枢神経系バイオマーカー市場は今後数年間で持続的な成長が見込まれます。

セグメント

バイオマーカータイプ（安全性、有効性、検証、その他のバイオマーカー）、用途（疾患診断、創薬開発、個別化治療、その他の用途）、最終用途（病院・診療所、診断研究所、学術研究機関、その他の最終用途）

調査対象企業の例

• AbaStarMDx Inc.
• AbbVie Inc.
• Abcam plc
• Abiant, Inc.
• Agilent Technologies, Inc.
• Avacta Group plc
• Banyan Biomarkers
• Biogen Inc.
• Biohaven Pharmaceuticals
• BioNTech SE
• Bio-Rad Laboratories, Inc.
• Biovista
• BrainScope Company, Inc.
• Charles River Laboratories International, Inc.
• Diagenic ASA
• EnCor Biotechnology
• Enzo Biochem Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Johnson & Johnson Services, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Central Nervous System Biomarkers Market to Reach US$8.8 Billion by 2030

The global market for Central Nervous System Biomarkers estimated at US$5.9 Billion in the year 2024, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Safety Biomarker, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Efficacy Biomarker segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 11.1% CAGR

The Central Nervous System Biomarkers market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Central Nervous System Biomarkers Market - Key Trends & Drivers Summarized

Why Is the Demand for Central Nervous System Biomarkers Increasing?

The rising prevalence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and traumatic brain injuries is a significant factor driving the demand for central nervous system (CNS) biomarkers. These biomarkers play an essential role in early diagnosis, disease progression monitoring, and treatment efficacy assessment. With an aging global population and increasing awareness of neurodegenerative diseases, the need for precise diagnostic tools has never been higher. Additionally, pharmaceutical and biotechnology companies are intensifying their research and development (R&D) efforts to identify novel biomarkers for personalized medicine. The rise in demand for targeted therapies has prompted greater investments in biomarker discovery, particularly in the field of neurodegenerative and psychiatric disorders. As precision medicine gains traction, CNS biomarkers are set to become indispensable in guiding treatment decisions and improving patient outcomes.

How Are Technological Advancements Enhancing CNS Biomarker Research?

Innovations in omics technologies, including genomics, proteomics, and metabolomics, are revolutionizing CNS biomarker research. High-throughput sequencing and advanced molecular profiling techniques are enabling the identification of novel biomarkers with higher specificity and sensitivity. Artificial intelligence (AI) and machine learning are also being employed to analyze vast datasets, improving the accuracy of biomarker-based diagnostics. Moreover, liquid biopsy techniques and non-invasive cerebrospinal fluid (CSF) biomarker assays are gaining popularity, offering less invasive methods for detecting neurological diseases. The integration of digital health technologies, including wearable biosensors and remote monitoring tools, is expanding the scope of biomarker applications. These advancements are expected to accelerate the commercialization of CNS biomarkers and improve the overall efficiency of neurological disease management.

What Market Trends Are Driving the Growth of CNS Biomarkers?

The growing adoption of biomarker-driven drug development is one of the key trends shaping the CNS biomarker market. Pharmaceutical companies are increasingly incorporating biomarkers into clinical trials to improve drug efficacy and patient stratification. Regulatory agencies such as the FDA and EMA are also supporting biomarker validation programs, facilitating faster drug approvals and personalized treatment strategies. Another significant trend is the rise of multi-modal biomarker approaches that combine molecular, imaging, and digital biomarkers. Advances in neuroimaging techniques, such as PET and MRI-based biomarkers, are enabling more accurate visualization of disease progression, particularly in conditions like Alzheimer’s and multiple sclerosis. Additionally, collaborations between academia, biotech firms, and healthcare institutions are fostering innovation and accelerating biomarker discovery and validation.

What Are the Key Growth Drivers in the Central Nervous System Biomarkers Market?

The growth in the Central Nervous System Biomarkers market is driven by several factors, including the rising burden of neurological disorders, the growing adoption of precision medicine, and technological advancements in biomarker discovery. The increasing demand for early diagnostic solutions and the expansion of biomarker-based drug development pipelines are further fueling market growth. Moreover, regulatory push for biomarker standardization and validation is encouraging pharmaceutical companies to integrate biomarkers into clinical trials. The expansion of biomarker-based companion diagnostics, particularly in neurodegenerative and psychiatric disorders, is creating new opportunities for market players. As the healthcare industry continues to prioritize early disease detection and personalized treatment strategies, the CNS biomarker market is expected to experience sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Central Nervous System Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biomarker Type (Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Biomarkers); Application (Disease Diagnosis Application, Drug Discovery and Development Application, Personalized Medicines Application, Other applications); End-Use (Hospitals and Clinics, Diagnostic Laboratories End-Use, Academic and Research Institutes End-Use, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbaStarMDx Inc.
• AbbVie Inc.
• Abcam plc
• Abiant, Inc.
• Agilent Technologies, Inc.
• Avacta Group plc
• Banyan Biomarkers
• Biogen Inc.
• Biohaven Pharmaceuticals
• BioNTech SE
• Bio-Rad Laboratories, Inc.
• Biovista
• BrainScope Company, Inc.
• Charles River Laboratories International, Inc.
• Diagenic ASA
• EnCor Biotechnology
• Enzo Biochem Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Johnson & Johnson Services, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Central Nervous System Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Neurological Disorders Propels Demand for Early and Accurate CNS Diagnostics
  • Technological Advancements in Imaging, Genomics, and Proteomics Drive Biomarker Discovery
  • Increased Investment in Neurodegenerative Disease Research Strengthens Pipeline for CNS Biomarkers
  • Regulatory Approvals and Companion Diagnostic Guidelines Spur Clinical Adoption of Biomarker Tests
  • Partnerships Between Biotech Firms and Academic Institutions Accelerate Translational Research
  • Growth in Personalized Medicine and Precision Neurology Expands Addressable Market for Biomarkers
  • Integration with Digital Health Tools and Wearable Devices Enhances Real-Time Monitoring Capabilities
  • Global Expansion of Biobanks and Patient Registries Facilitates Large-Scale Biomarker Validation
  • Pharmaceutical Interest in Biomarker-Based Drug Development Drives Market for Predictive Diagnostics
  • Clinical Utility in Treatment Response Monitoring Generates Demand for Longitudinal Biomarker Use
  • Quality Control and Standardization Issues Propel Innovation in Biomarker Assay Platforms
  • AI and Machine Learning in Biomarker Data Analysis Accelerate Insights and Clinical Decision Support
  • Expansion of Point-of-Care and Home-Based Testing Solutions Opens New Channels for Biomarker Utilization
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Central Nervous System Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Central Nervous System Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Safety Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Safety Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Safety Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Efficacy Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Efficacy Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Efficacy Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Validation Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Validation Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Validation Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Disease Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Disease Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Disease Diagnosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Personalized Medicines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Personalized Medicines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Personalized Medicines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• JAPAN
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• CHINA
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• EUROPE
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Central Nervous System Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• FRANCE
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• GERMANY
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Central Nervous System Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• INDIA
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Central Nervous System Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Central Nervous System Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
• AFRICA
  • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030

IV. COMPETITION